100 related articles for article (PubMed ID: 23128395)
21. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
23. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
[TBL] [Abstract][Full Text] [Related]
24. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
26. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
27. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration.
Lavigne MC; Grimsby JL; Eppihimer MJ
J Cardiovasc Pharmacol; 2012 Feb; 59(2):165-74. PubMed ID: 21983747
[TBL] [Abstract][Full Text] [Related]
28. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
Hsu YL; Kuo PL; Tzeng TF; Sung SC; Yen MH; Lin LT; Lin CC
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e290-9. PubMed ID: 18522681
[TBL] [Abstract][Full Text] [Related]
29. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
Papewalis C; Wuttke M; Schinner S; Willenberg HS; Baran AM; Scherbaum WA; Schott M
Horm Metab Res; 2009 Oct; 41(10):752-6. PubMed ID: 19513966
[TBL] [Abstract][Full Text] [Related]
30. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
[TBL] [Abstract][Full Text] [Related]
31. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
32. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
34. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
35. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
[TBL] [Abstract][Full Text] [Related]
36. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
[TBL] [Abstract][Full Text] [Related]
37. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Colaço B; Lopes C; Colaço A; Costa C; da Silva VM; Oliveira P; Santos L
Biomed Pharmacother; 2013 Mar; 67(2):116-21. PubMed ID: 23433853
[TBL] [Abstract][Full Text] [Related]
38. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
Wang CC; Chiang YM; Sung SC; Hsu YL; Chang JK; Kuo PL
Cancer Lett; 2008 Jan; 259(1):82-98. PubMed ID: 18023967
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
40. Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells.
Lee SJ; Cho YH; Park K; Kim EJ; Jung KH; Park SS; Kim WJ; Moon SK
Biochem Pharmacol; 2008 Jun; 75(12):2289-300. PubMed ID: 18468578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
